Interim Phase II Results of DNX-2401 + Pembrolizumab for Glioblastoma Shows Remarkable Results

Interim Phase II Results of DNX-2401 + Pembrolizumab for Glioblastoma Shows Remarkable Results (Onco’zine)

Preliminary results from the CAPTIVE / KEYNOTE-192 study (NCT02798406) dose escalation study evaluating a single intratumoral injection of DNX-2401 (tasadenoturev; UF startup DNAtrix) followed by standard dosing with pembrolizumab (Keytruda®; Merck Sharp & Dohme Corp/MSD) every three weeks to determine the optimal dose, safety, and efficacy in patients with recurrent glioblastoma, demonstrate that combination of the two agents is well tolerated and associated with promising survival.[1]*

Glioblastoma and gliosarcoma are the most common and aggressive forms of malignant brain tumor in adults and can be resistant to conventional therapies. The purpose of the CAPTIVE / KEYNOTE-192 study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds to one injection of DNX-2401, a genetically modified oncolytic adenovirus, when delivered directly into the tumor followed by intravenous administration of the immune checkpoint inhibitor pembrolizumab.

Learn more about Interim Phase II Results of DNX-2401 + Pembrolizumab for Glioblastoma Shows Remarkable Results.

X